Disease · MONDO_0000485

spasmodic dystonia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. spasmodic dystonia. Diseases, record MONDO_0000485. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0000485

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: spasmodic dystonia; Open Targets
Open Targets ID: MONDO_0000485; Open Targets
Other names: laryngeal dyskinesia, laryngeal dystonia, spasmodic dysphonia, spastic dysphonia; Open Targets
Disease Ontology: DOID:0050844; Disease Ontology
MeSH: D055154; MeSH
Orphanet: ORPHA:93961; Orphanet
Highest stage of its drugs: Phase 2/3, for 1 of its 7 drugs, from ClinicalTrials.gov; Open Targets

Drugs7

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
SODIUM OXYBATE	CHEMBL1200682	Small molecule	Phase 2/3	ClinicalTrials.gov	3	3	3	Drugs and targets
ONABOTULINUMTOXINA	CHEMBL1201574		Phase 1/2	ClinicalTrials.gov	2	2	1	Drugs and targets
DAXIBOTULINUMTOXINA	CHEMBL3707359		Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
ZINC GLUCONATE	CHEMBL3833377	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
DEXTROMETHORPHAN	CHEMBL52440	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
LORAZEPAM	CHEMBL580	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
BOTULINUM TOXIN TYPE A	CHEMBL4297862	Protein	Unknown	ClinicalTrials.gov	1	1	0	Drugs and targets

Targets21

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SNAP25	Synaptosomal-associated protein 25	3	Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme; Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor	Phase 1/2	https://conductscience.org/library/genes/6616	Drugs and targets
GABBR1	GABA-B receptor	1	GABA-B receptor agonist	Phase 2/3	https://conductscience.org/library/genes/2550	Drugs and targets
GABBR2	GABA-B receptor	1	GABA-B receptor agonist	Phase 2/3	https://conductscience.org/library/genes/9568	Drugs and targets
GABRA1	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Phase 1	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Phase 1	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Phase 1	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Phase 1	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Phase 1	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Phase 1	https://conductscience.org/library/genes/2559	Drugs and targets
GABRB1	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Phase 1	https://conductscience.org/library/genes/2560	Drugs and targets

1 to 10 of 21

See all 21 targets

Trials7

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03292458	Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor	Phase 2/3	117	2025-04-04	Spasmodic Dysphonia, Voice Tremor	SODIUM OXYBATE	Its record names the disease	ClinicalTrials.gov
NCT01961297	Voice Tremor in Spasmodic Dysphonia: Central Mechanisms and Treatment Response	Phase 2	53	2017-11-22	Spasmodic Dysphonia, Voice Tremor	SODIUM OXYBATE	Its record names the disease	ClinicalTrials.gov
NCT03543150	BOTOX® Drug Use Investigation (Spasmodic Dysphonia)		400		Dysphonia	ONABOTULINUMTOXINA	Its record names the disease	ClinicalTrials.gov
NCT00055549	Dextromethorphan to Treat Patients With Voice Spasms	Phase 1	65		Voice Disorders	DEXTROMETHORPHAN, LORAZEPAM	Open Targets' reading of its record	ClinicalTrials.gov
NCT05892770	Zinc Supplementation Prior to Botox Injections for Spasmodic Dysphonia	Phase 1/2	32		Spasmodic Dysphonia	ZINC GLUCONATE	Its record names the disease	ClinicalTrials.gov
NCT05158166	DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia	Phase 1/2	22		Adductor Spasmodic Dysphonia, Voice Disorders, Spasmodic Dysphonia	DAXIBOTULINUMTOXINA	Its record names the disease	ClinicalTrials.gov
NCT07041203	Extended-release Sodium Oxybate (Lumryz) in Spasmodic Dysphonia and Voice Tremor	Phase 1	8		Spasmodic Dysphonia, Laryngeal Dystonia, Voice Tremor	SODIUM OXYBATE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Spasmodic Dysphonia vs Spasmodic Dysphonia/Voice Tremor: deaths from any cause	0 of 28	0 of 22	50	NCT01961297	Trial comparisons
Spasmodic Dysphonia vs Spasmodic Dysphonia/Voice Tremor: serious adverse events	0 of 28	0 of 22	50	NCT01961297	Trial comparisons
Spasmodic Dysphonia vs Spasmodic Dysphonia/Voice Tremor: Number of Participants Who Reported Positive Effects.	17 of 23	20 of 22	45	NCT01961297	Trial comparisons

Papers from its trials6

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
27808415	RESULT	1	PubMed
40265962	DERIVED	1	PubMed
37755979	DERIVED	1	PubMed
37448353	DERIVED	1	PubMed
30382161	DERIVED	1	PubMed
25929664	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0000485

GET https://conductscience.org/api/diseases/v1/MONDO_0000485/targets?page=2

API reference For AI assistants